Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1132035

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Care Networks
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	264406
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:34:05 question first ministerially corrected 19/06/2019 08:36:30 answering member 4455 label Biography information for Seema Kennedy previous answer version 123829 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1132037

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Care Networks: Rural Areas
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what population exceptions are in place for Primary Care Networks covering large rural and remote areas.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	264408
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>NHS England has allowed rurality as an exception for meeting the definition of a Primary Care Network (PCN). As set out in the Network Contract Direct Enhanced Service (under paragraph 3.2) commissioners may waiver the 30,000-minimum population “where a PCN serves a natural community which has a low population density across a large rural and remote area”.</p><p>Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:30:48 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125380

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, how many times his Department has sought information relating to bespoke medicines from small producers with an annual NHS turnover of less than £5 million; and whether he plans to make an assessment on the potential merits of requiring all small producers to automatically supply quarterly information on those medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252063
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) prescribe when manufacturers, importers and wholesalers of special medicinal products are required to provide information. Since the Regulations entered into force, quarterly information has been received in November 2018 and February 2019 and information is again due at the end of May 2019. The requirement to provide quarterly sales, purchase and volume information about special medicinal products already applies to all manufacturers, importers and wholesalers regardless of their size. Therefore, there is no need for an assessment on the potential merits of requiring all small producers to automatically supply quarterly information.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 252064 question first answered 13/05/2019 15:40:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125381

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, what criteria his Department uses to decide on which small producers to seek information from.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252064
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) prescribe when manufacturers, importers and wholesalers of special medicinal products are required to provide information. Since the Regulations entered into force, quarterly information has been received in November 2018 and February 2019 and information is again due at the end of May 2019. The requirement to provide quarterly sales, purchase and volume information about special medicinal products already applies to all manufacturers, importers and wholesalers regardless of their size. Therefore, there is no need for an assessment on the potential merits of requiring all small producers to automatically supply quarterly information.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 252063 question first answered 13/05/2019 15:40:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125382

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, what steps he is taking to ensure that (a) wholesalers and (b) importers are providing his Department with information on medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252065
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department is undertaking an exercise to ensure that all companies that are required to provide quarterly information under the Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) are doing so. Where they are not, the Department will consider taking the appropriate action provided for in the Regulations.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 15:39:14 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125383

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to use the powers set out in the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to seek information on the special health service medicine selected yy medical professional bodies.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252066
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department selects medicines to be included in the quarterly collection of information on special medicinal products based on the level of prescribing. If medical professional bodies have selected special medicinal products that they believe should be included with a reimbursement price in Part VIIIB of the Drug Tariff then the Department will consider including those products in the quarterly collection, but only if those products are prescribed in primary care. If products are not prescribed in primary care then there is no sales, purchase and volume information for special medicinal products supplied to primary care that can be provided by suppliers in the quarterly information collection.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:08:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125053

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his Department's timetable is for the national roll-out of non-invasive prenatal testing, as recommended by the UK National Screening Committee in November 2016.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	251394
	answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The procurement for providers to undertake the evaluative roll out of non-invasive prenatal testing (NIPT) in England is currently being undertaken on behalf of Public Health England by NHS England as part of the Genomic Testing Services procurement.</p><p>There has been a legal challenge which relates only to the NIPT element of the current procurement which means that there is currently an automatic suspension in place. The extent of the delay will depend on how the litigation proceeds.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:37:43 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125054

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genomics: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has plans to undertake a public consultation with stakeholders on the development of the National Genomic Healthcare Strategy.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	251395
	answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>In developing the National Genomic Healthcare Strategy, the Government will undertake wide ranging and comprehensive engagement, involving detailed discussions with patient and public groups, researchers, charities and industry. This will be guided by the National Genomics Board, which oversees the Government’s work to maintain the United Kingdom’s position as the world’s leading centre for genomic medicine and research.</p><p>Although this does not involve a formal public consultation document, patients and the public will be key to developing the strategy, and we will utilise a wide range of existing public and patient engagement groups to do so.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/05/2019 15:56:28 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4249 label Biography information for Anne Marie Morris

1121932

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress is being made on the development of the UK CAR-T Cell Therapy Strategy; when stakeholders will be invited to participate in the development of that strategy; and when he plans to publish that strategy.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	245799
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>The National Health Service in England is one of the first health services in the world to deliver Chimeric Antigen Receptor T Cell (CAR-T) Therapy. The first patient began their treatment in October 2018 for B cell acute lymphoblastic leukaemia. NHS England continues to focus on supporting implementation of these CAR-T products in the first wave of treatment centres, and are preparing for a potential second wave of treatment centres to begin delivering the treatment later in 2019. There are no plans to develop or publish a strategy.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 25/04/2019 14:04:42 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1108771

	registered interest
	date	01/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when guidance will be made available to pharmacists on the Serious Medicines Shortage Protocols.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	239239
	answer	answer is ministerial correction date of answer 04/04/2019 answer text <p>Serious Shortage Protocols are an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p> </p><p>Operational guidance is still being developed with stakeholders, including where any protocol(s) would be published. The use of a Serious Shortage Protocol has not, to date, been required.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 239240 239241 question first answered 04/04/2019 11:10:59 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4249 label Biography information for Anne Marie Morris